WuXi Biologics
Offering End-to-End Solutions
WuXi Vaccines Receives Brazil’s ANVISA GMP Certification
Suzhou, February 12, 2026 –WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill...WuXi Vaccines and MSD Enter into Agreement on Ireland Facility
Dundalk, Ireland, January 6, 2025 – WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), today announced that it has entered into a definitive agreement with MSD International GmbH...WuXi Vaccines Establishes New Vaccines CDMO Facility in China
Suzhou, China, Nov. 15, 2022 – WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed’s manufacturing facility in Suzhou will be...WuXi Vaccines Wins the “Best Vaccine CMO Award of the Year” at the Asia Pacific Vaccine Excellence Awards 2022
SHANGHAI, Nov. 9, 2022 – WuXi Vaccines, a global leading vaccines Contract Development and Manufacturing Organization (CDMO), received the ‘Best Vaccine CMO of the Year” at Asia-Pacific Vaccine Excellence Awards (AVEA) 2022. AVEA 2022 recognises the outstanding...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?